Ul­tragenyx wins pri­or­i­ty re­view for buro­sum­ab; Gen­fit rais­ing €150M for PhI­II NASH study

→ Ul­tragenyx $RARE and its part­ners at Ky­owa Hakko Kirin land­ed a pri­or­i­ty re­view for buro­sum­ab to treat pe­di­atric and adult pa­tients with X-Linked Hy­pophos­phatemia. The ac­cel­er­at­ed PR gives them a shot at an April 17, 2018 PDU­FA date.

→ Gen­fit (Eu­ronext: GN­FT) is rais­ing €150 mil­lion so it can wrap up its Phase III for elafi­bra­nor in NASH and take the da­ta to reg­u­la­tors.

→ France’s Bio­phytis has raised €10.4 mil­lion for mid-stage stud­ies of its drugs for age-re­lat­ed dis­eases. The biotech is work­ing on sar­cope­nia and age-re­lat­ed mac­u­lar de­gen­er­a­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER